Get the Stockscreener App
28.51
0.39%
0.11
Pre-market:
29.69
1.18
+4.14%
Ionis Pharmaceuticals Inc stock is traded at $28.51, with a volume of 950.54K.
It is up +0.39% in the last 24 hours and down -13.37% over the past month.
Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and Biogen brought Spinraza to market in 2016 as a treatment for spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019). Ionis and AstraZeneca launched polyneuropathy drug Wainua in 2024. Ionis received FDA approval in 2024 for Tryngolza for a rare high-triglyceride syndrome, marking its first independent launch.
See More
Previous Close:
$28.40
Open:
$28.04
24h Volume:
950.54K
Relative Volume:
0.55
Market Cap:
$4.56B
Revenue:
$705.14M
Net Income/Loss:
$-453.90M
P/E Ratio:
-9.3783
EPS:
-3.04
Net Cash Flow:
$-551.29M
1W Performance:
-0.59%
1M Performance:
-13.37%
6M Performance:
-26.90%
1Y Performance:
-29.92%
1-Day Range:
$27.90
$29.06
1-Week Range:
$27.57
$29.06
52-Week Range:
$23.95
$52.34
Ionis Pharmaceuticals Inc Stock (IONS) Company Profile
Name
Ionis Pharmaceuticals Inc
Sector
Industry
Phone
(760) 931-9200
Address
2855 GAZELLE COURT, CARLSBAD, CA
Compare IONS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
IONS
Ionis Pharmaceuticals Inc
|
28.51 | 4.56B | 705.14M | -453.90M | -551.29M | -3.04 |
|
VRTX
Vertex Pharmaceuticals Inc
|
477.52 | 127.47B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
561.49 | 62.43B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
595.70 | 37.03B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
232.75 | 31.06B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
229.22 | 26.16B | 3.81B | -644.79M | -669.77M | -6.24 |
Ionis Pharmaceuticals Inc Stock (IONS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-07-25 | Initiated | H.C. Wainwright | Buy |
| Mar-31-25 | Initiated | Redburn Atlantic | Neutral |
| Aug-02-24 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Jul-24-24 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Jul-16-24 | Resumed | Jefferies | Buy |
| Jun-14-24 | Upgrade | Bernstein | Underperform → Mkt Perform |
| Apr-10-24 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Jan-02-24 | Upgrade | BofA Securities | Neutral → Buy |
| Oct-23-23 | Upgrade | BofA Securities | Underperform → Neutral |
| Sep-29-23 | Initiated | Raymond James | Strong Buy |
| Jul-31-23 | Upgrade | Citigroup | Neutral → Buy |
| Jun-07-23 | Resumed | Piper Sandler | Overweight |
| May-04-23 | Upgrade | Citigroup | Sell → Neutral |
| Mar-21-23 | Initiated | Bernstein | Underperform |
| Dec-21-22 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Sep-09-22 | Resumed | Morgan Stanley | Overweight |
| Jul-18-22 | Resumed | Oppenheimer | Outperform |
| Mar-31-22 | Resumed | Piper Sandler | Overweight |
| Mar-01-22 | Initiated | Citigroup | Sell |
| Mar-01-22 | Initiated | Guggenheim | Buy |
| Feb-01-22 | Downgrade | BofA Securities | Buy → Underperform |
| Dec-14-21 | Upgrade | William Blair | Mkt Perform → Outperform |
| May-07-21 | Upgrade | UBS | Sell → Neutral |
| Mar-01-21 | Upgrade | Barclays | Underweight → Equal Weight |
| Dec-16-20 | Initiated | UBS | Sell |
| Dec-15-20 | Upgrade | Cowen | Market Perform → Outperform |
| Sep-14-20 | Resumed | JP Morgan | Neutral |
| Sep-02-20 | Initiated | The Benchmark Company | Hold |
| Jun-01-20 | Resumed | Oppenheimer | Outperform |
| May-13-20 | Initiated | RBC Capital Mkts | Outperform |
| Mar-05-20 | Initiated | Citigroup | Buy |
| Dec-13-19 | Initiated | Oppenheimer | Outperform |
| Nov-13-19 | Initiated | BofA/Merrill | Buy |
| Nov-07-19 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| Sep-10-19 | Upgrade | Bernstein | Mkt Perform → Outperform |
| Aug-08-18 | Reiterated | Stifel | Hold |
| Aug-07-18 | Reiterated | Stifel | Hold |
| May-08-18 | Downgrade | Evercore ISI | Outperform → In-line |
| Oct-06-17 | Resumed | Goldman | Sell |
| Aug-17-17 | Initiated | Evercore ISI | Outperform |
| Aug-09-17 | Reiterated | Stifel | Hold |
| Mar-10-17 | Downgrade | Goldman | Neutral → Sell |
| Dec-28-16 | Reiterated | BMO Capital Markets | Outperform |
| Dec-27-16 | Reiterated | Leerink Partners | Mkt Perform |
View All
Ionis Pharmaceuticals Inc Stock (IONS) Latest News
Is Ionis Pharmaceuticals (NASDAQ:IONS) Using Debt In A Risky Way? - simplywall.st
Ionis Pharmaceuticals EVP Jenne Kyle sells $85,533 in stock - Investing.com Australia
Ionis Pharmaceuticals EVP Jenne Kyle sells $85,533 in stock By Investing.com - Investing.com Canada
Ionis Pharmaceuticals EVP Brian Birchler sells $19,291 in stock By Investing.com - Investing.com South Africa
Ionis Pharmaceuticals EVP Joseph Baroldi sells $111,555 in stock By Investing.com - Investing.com South Africa
Ionis Pharmaceuticals EVP Joseph Baroldi sells $111,555 in stock - Investing.com
Lobbying Update: $90,000 of IONIS PHARMACEUTICALS INC. lobbying was just disclosed - Nasdaq
Ionis to hold first quarter 2025 financial results webcast - BioSpace
Ionis Q1 2025 Earnings Call: Key Date and Details for Investors Revealed - Stock Titan
Ionis Pharmaceuticals (IONS) Sees Price Target Cut by Morgan Sta - GuruFocus
Ionis Pharmaceuticals (IONS) Surges 8.9%: Is This an Indication of Further Gains? - MSN
Polycythemia Vera Market to Show Remarkable Growth Trends from - openPR.com
Global Antisense & RNAi Therapeutics Market to Witness Massive - openPR.com
Acromegaly Pipeline 2025: Detailed Clinical Trials - openPR.com
Amyotrophic Lateral Sclerosis Pipeline 2025: MOA and ROA - openPR.com
Transthyretin Amyloid Cardiomyopathy Treatment Market Set - openPR.com
Ionis at Needham Conference: Strategic Growth and Future Prospects By Investing.com - Investing.com UK
Ionis Pharmaceuticals initiated with a Buy at H.C. Wainwright - MSN
HC Wainwright & Co. Initiates Coverage of Ionis Pharmaceuticals (IONS) with Buy Recommendation - MSN
Drugmaker Ionis Pharmaceuticals Garners Analyst Praise For 'Pipeline Depth' - Benzinga
This Reddit Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday - Benzinga
Ionis Pharma stock hits 52-week low at $26.65 amid market challenges - Investing.com
H.C. Wainwright initiates coverage for Ionis Pharma with 'buy' rating citing pending drug launches - TradingView
H.C. Wainwright initiated coverage on Ionis Pharma with a new price target - Quantisnow
HC Wainwright Initiates Ionis Pharmaceuticals With Buy Rating, $45 Price Target - MarketScreener
H.C. Wainwright sets Ionis stock Buy rating, $45 target By Investing.com - Investing.com UK
Ionis Pharmaceuticals Enters Oversold Territory (IONS) - Nasdaq
Hereditary Angioedema Pipeline: Over 20 Leading Companies - openPR.com
Ionis to host expert panel discussion on sHTG - The Joplin Globe
Leading Medical Experts Reveal Latest Insights on Severe HTG Treatment Landscape - Stock Titan
Treatment-resistant Hypertension Market Growth Projections 2024-2034: DelveInsight Analysis | Idorsia Pharma, Ionis Pharma, KBP Biosciences, KBP Biosciences, Quantum Genomics - Barchart.com
Biogen’s Investigational Tau-Targeting Therapy BIIB080 Receives FDA Fast Track Designation for the Treatment of Alzheimer’s Disease - Biogen
10 Promising Biotech Stocks to Invest in (April 2025) - Securities.io
Redburn Atlantic Initiates Coverage of Ionis Pharmaceuticals (IONS) with Neutral Recommendation - MSN
Assessing Ionis Pharmaceuticals: Insights From 8 Financial Analysts - Benzinga
Redburn Atlantic initiated coverage on Ionis Pharma with a new price target - Quantisnow
Redburn Atlantic Initiates Ionis Pharmaceuticals at Neutral With $39 Price Target - MarketScreener
Ionis to present at upcoming investor conferences - The Joplin Globe
Redburn initiates Ionis stock with Neutral, sets $39 target - Investing.com India
11 Best Gene Therapy Stocks to Buy According to Analysts - Insider Monkey
IONS Out-Licenses ex-U.S. Rights for Rare Disease Drug Tryngolza to Sobi - MSN
Ionis expands partnership with Sobi to include olezarsen commercialization outside the U.S. - MSN
Catalyst (CPRX) Up 14.7% Since Last Earnings Report: Can It Continue? - Yahoo Finance
RNA Biotechs: Current State And Outlook - Seeking Alpha
Ionis and Sobi agree on olezarsen commercialisation - Yahoo
Ionis licenses olezarsen to Sobi for global reach By Investing.com - Investing.com South Africa
Ionis Pharmaceuticals Inc Stock (IONS) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.15%
4.32%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):